Related Experiment Video

Updated: Jul 14, 2026

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
08:47

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer

Published on: April 21, 2022

RhDNase before airway clearance therapy improves airway patency in children with CF

Lianne J van der Giessen1, Johan C de Jongste, Rik Gosselink

  • 1Department of Paediatric Physiotherapy, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands. l.vandergiessen@erasmusmc.nl

Pediatric Pulmonology
|May 31, 2007
PubMed

Insights

Inhaling recombinant human DNAse (rhDNase) before airway clearance therapy (ACT) significantly improves lung function in children with cystic fibrosis. This timing offers additional benefits beyond regular rhDNase maintenance therapy.

Area of Science:

  • Pulmonary Medicine
  • Pediatric Respiratory Care
  • Cystic Fibrosis Research

Background:

  • Optimal timing for recombinant human DNAse (rhDNase) nebulization with airway clearance therapy (ACT) in cystic fibrosis (CF) is not well-established.
  • Understanding this timing is crucial for maximizing therapeutic benefits in CF patients.

Purpose of the Study:

  • To compare the efficacy of rhDNase inhalation administered before ACT versus after ACT in pediatric CF patients.
  • To evaluate the impact of rhDNase timing on peripheral airway function and respiratory symptoms.

Main Methods:

  • A randomized, double-blind, double-dummy, crossover study was conducted.
  • Participants received rhDNase either 30 minutes before or immediately after ACT for three weeks, then switched protocols.
  • Primary endpoint was maximal expiratory flow at 25% of forced vital capacity (MEF25) predicted; secondary endpoints included cough and sputum production.

Main Results:

  • Twenty-four children with CF completed the study.
  • Inhaling rhDNase before ACT resulted in a statistically significant improvement in MEF25 %pred (58.3%) compared to rhDNase after ACT (52.5%, p=0.01).
  • No significant differences were observed for other measured variables, including cough and sputum production.

Conclusions:

  • Administering rhDNase before ACT enhances peripheral airway patency in children with CF.
  • This pre-ACT nebulization provides an added therapeutic benefit independent of existing maintenance rhDNase therapy.
Abstract

More Related Videos

In vivo Evaluation of Mucociliary Clearance in Mice06:35

In vivo Evaluation of Mucociliary Clearance in Mice

Published on: December 18, 2020

Real-Time, Semi-Automated Fluorescent Measurement of the Airway Surface Liquid pH of Primary Human Airway Epithelial Cells10:18

Real-Time, Semi-Automated Fluorescent Measurement of the Airway Surface Liquid pH of Primary Human Airway Epithelial Cells

Published on: June 13, 2019

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Suctioning the Nasopharyngeal Airway01:29

Suctioning the Nasopharyngeal Airway

Nasopharyngeal suctioning is a procedure to remove secretions from the upper part of the respiratory tract that the patient cannot clear independently. It helps maintain airway patency and prevents complications such as aspiration pneumonia.
Equipment Required
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...